Dogwood Therapeutics (DWTX) investor relations material

Executive summary

• HalneuronⓇ is in Phase 2b for chemotherapy-induced neuropathic pain (CINP) with 217 patients enrolled and top-line results expected in fall 2026; a long-term extension study is underway.

• SP16 is advancing to Phase 1 for chemotherapy-induced peripheral neuropathy (CIPN), with IND approval and trial fully funded by the National Cancer Institute.

• Announced a global partnership for legacy antiviral assets, potentially worth up to $100M, with first payment of $100,000 from PRIDCor License Agreement received in July 2026.

• No product revenue to date; Q2 2026 revenue was $5.9M, up from $5.0M in Q2 2025.

• Cash on hand of $9.6 million as of June 30, 2026, expected to fund operations into Q4 2026.

Financial highlights

• Net loss of $11.5 million for Q2 2026, driven by higher R&D and impairment charges, compared to $3.8 million in Q2 2025.

• Operating expenses for Q2 2026 were $14.1 million, up from $3.9 million in Q2 2025, mainly due to a $9.2 million IPR&D impairment.

• Research and development expenses rose to $3.2M from $2.6M year-over-year, mainly due to increased Halneuron study costs.

• General and administrative expenses increased to $1.6M from $1.3M year-over-year.

• Cash used in operating activities was $8.2 million for the six months ended June 30, 2026.

Outlook and guidance

• Top-line results from the HalneuronⓇ Phase 2b CINP trial expected in fall 2026, with over 220 patients targeted for enrollment.

• SP16 Phase 1b trial to begin in H2 2026, fully funded by the National Cancer Institute.

• Cash runway extends into Q4 2026; additional funding required to continue operations and clinical development beyond that.

• No anticipated product revenue in the near term; future revenue dependent on successful clinical development and commercialization.